Clinical Trials Search Results
- A Phase 2/3, Interventional safety, pharmacokinetics, and efficacy, open-label, multi-center, single-arm study to investigate orally administered PF-07321332 (Nirmatrelvir)/Ritonavir in non-hospitalized symptomatic pediatric participants with COVID-19 who are at risk of progression to severe disease
To compare the efficacy of nirmatrelvir (PF-07321332)/ritonavir to placebo for the treatment of symtomatic COVID-19 in non- hospitalized pediatric participants with COVID-19 who are at risk of progression to severe disease. Patients are randomized 1:1 and will receive placebo or the investigational product orally for 5 days. Patients will complete in-person and remote follow-up visits including assessments such as nasapharyngeal swabs, blood draws, and physical exams. Participants will be compensated for their time.
- A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity.
Meningococcal Group B Vaccine trial for teens, ages 16-18 years.
- Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia for 12 weeks.
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
The study investigators are interested in learning more about how drugs act in the bodies of children and young adults in hopes to find the most safe and effective dose for children.
- Totient - Identifying naturally evolving human antibodies to test potential efficacy at neutralizing SARS – COV-2
Identifying naturally evolving human antibodies to test potential efficacy at neutralizing SARS – COV-2
- Understanding the Long-term Impact of COVID on Children and Families
Research efforts focus on the long-term effects of COVID-19, called Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Long COVID is a form of PASC, and refers to symptoms that persist for weeks or months after the acute infection. Research teams, including the Avera Research Institute, study and share data in real time, providing the scale needed to get answers to help alleviate suffering as fast as possible.
